When "Nothing Left to Try" Isn't the End
At 65, she had already been through bladder removal surgery. Then her cancer came back in her lungs. Chemotherapy did not work. Immunotherapy did not work. Her doctors discussed hospice.
She said yes to one more surgery instead.
A Rare Cancer With No Playbook
Most bladder cancers are urothelial — they arise from the inner lining of the bladder. But squamous cell carcinoma (SqCC) of the bladder is different. It accounts for only about 3 to 5 percent of all bladder cancers in high-income countries and is much rarer in a "pure" form, meaning no mixed cancer types present.
SqCC behaves differently from urothelial cancer. It tends to be caught at a later stage, it responds less predictably to standard chemotherapy drugs, and there is no widely agreed treatment plan for cases where it has already spread. Oncologists (cancer doctors) often find themselves adapting protocols designed for other cancers and hoping for the best.
Old Way: Systemic Treatment Until Nothing Works
When bladder cancer spreads to distant sites like the lungs, the standard approach is systemic therapy — chemotherapy or immunotherapy designed to attack cancer throughout the entire body. Surgery on those distant sites, called metastases (secondary tumors that have traveled from the original cancer), is generally reserved for very specific situations and very specific cancers.
For SqCC of the bladder, the role of that kind of surgery — called metastasectomy — is almost completely undefined. There are no clinical trials. There are barely any published cases.
But here's the twist: sometimes the absence of evidence is not the same as evidence of absence.
After her cancer failed to respond to two lines of treatment, imaging showed two substantial tumors in her lungs. Surgeons performed a pulmonary bilobectomy — removal of two lobes of the lung. Think of the lung as a bunch of grapes: surgeons removed two clusters, leaving the rest intact.
This doesn't mean lung surgery is a standard or widely available option for people in this situation — this case is exceptional in many ways.
The goal was not palliative (comfort-focused) — it was curative. And that gamble, in this one patient, paid off.
This is a case report of a single 65-year-old woman treated at one medical center. She had radical cystectomy (bladder removal) for pure SqCC, developed two lung metastases shortly afterward, received platinum-based chemotherapy followed by immunotherapy without response, and then underwent pulmonary bilobectomy. She was followed for more than two years after surgery.
After surgery, her scans showed no remaining cancer. That complete response has held for over two years. She has not required additional treatment. Her performance status — a measure of how well a person can carry out daily activities — improved after surgery compared to where she was during chemotherapy.
The authors reviewed existing literature on metastasectomy for bladder cancer more broadly. Very few cases have been reported, and outcomes vary. But in carefully selected patients — those whose cancer is limited to a small number of sites and who are physically strong enough for surgery — there are hints that aggressive surgical intervention may sometimes produce durable results that drugs cannot.
That's Not the Full Story
There is no way to know, from one case, whether surgery caused the remission or whether this patient's biology would have behaved differently regardless. Survivorship reporting in oncology is vulnerable to selection bias — the cases that work are published; the ones that do not are often not.
This patient was selected for surgery precisely because her doctors believed she had a reasonable chance. Not every patient with metastatic bladder SqCC would qualify.
If you or a loved one has a rare bladder cancer that has spread and is not responding to chemotherapy or immunotherapy, this case is a reason to ask questions — not to assume surgery is an option, but to have a thorough conversation with a specialist about whether any aggressive local treatments have been considered.
Getting a second opinion at a major cancer center with experience in rare bladder cancers is worth the effort. Oncologists who see more of these rare cases are more likely to be aware of emerging, non-standard options.
A single case report cannot establish cause and effect. It cannot tell us what percentage of similar patients would benefit from surgery, what the risks are at a population level, or which patients are most likely to respond. Publication bias — the tendency for positive outcomes to be reported more than negative ones — is a real concern in rare cancer literature. This case should be seen as hypothesis-generating, not practice-changing.
The authors call for prospective studies (planned, forward-looking research rather than after-the-fact case reports) to define which patients with metastatic bladder SqCC might benefit from surgical resection of metastases. Building registries of rare bladder cancer cases across multiple medical centers would help accumulate the numbers needed to draw real conclusions. Until then, decisions will continue to be made case by case — which makes shared decision-making between patient and oncologist more important than ever.
